Hirokuni Takano

Amplification of <i>PVT1</i> Contributes to the Pathophysiology of Ovarian and Breast Cancer

Yinghui Guan, Wen-Lin Kuo, Jackie L. Stilwell et al. · Clinical Cancer Research · 2007 · 351 citations · Full text

Medicine, Genetics, Oncology +16

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12

Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers

Eiryo Kawakami, Junya Tabata, Nozomu Yanaihara et al. · Clinical Cancer Research · 2019 · 232 citations

Medicine, Gynecology, Oncology +17

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 86 citations · Full text

Medicine, Gynecology, Oncology +11

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata et al. · Institutional Repositories DataBase (IRDB) · 2021 · 82 citations · Full text

Medicine, Oncology, Pharmacology +16